Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
PURITAN MEDICAL

Researchers Characterize PrimPol, a Novel Human DNA Polymerase

By BiotechDaily International staff writers
Posted on 19 Nov 2013
PrimPol, a novel enzyme cloned in human cells, has been shown to initiate DNA chains with deoxynucleotides unlike regular primases, which exclusively use ribonucleotides.

Investigators at the biotechnology company SYGNIS AG (Madrid, Spain; and Heidelberg, Germany) in collaboration with researchers at the Spanish National Research Council (Madrid) recently isolated and characterized PrimPol.

They reported in the October 24, 2013, online edition of the journal Molecular Cell that PrimPol functioned as both DNA primase and DNA polymerase, and demonstrated high tolerance to damaged DNA. The primase function of PrimPol allowed it to begin reading and copying DNA without the need for random ribonucleotide primers, as required by all other commercially available polymerases. The use of random primers can bias sequencing and amplification results. The polymerase function of PrimPol displayed high specific activity, being extremely efficient when copying DNA strands with different lesions, such as abasic sites or 8-oxoguanine.

Subcellular fractionation and immunodetection studies showed that PrimPol could be found in both nuclear and mitochondrial DNA compartments. Its activity was detectable in mitochondrial lysates from human and mouse cells but was absent from mitochondria derived from mice that had been genetically engineered to lack the PRIMPOL gene. PRIMPOL gene silencing or ablation in human and mouse cells impaired mitochondrial DNA replication.

Senior author Dr. Luis Blanco, research professor at the Spanish National Research Council, said, "I am convinced that this fantastic enzyme will open numerous novel applications in the field of molecular biology, some of them we can only hint at this moment given the highly innovative potential of its key features."

SYGNIS AG is currently developing a new thermostable version of the enzyme that is expected to make an important contribution to the DNA amplification and sequencing field.

Related Links:

SYGNIS AG 
Spanish National Research Council



Channels

Drug Discovery

view channel
Image: A new micelle delivery system for the protective polyphenols resveratrol and quercetin (mRQ) may have value in cancer chemotherapy (Photo courtesy of Oregon State University).

Micelles Containing Resveratrol and Quercetin Reverse Doxorubicin Cardiotoxicity

Cancer researchers blocked the toxic effects of the cancer drug doxorubicin (DOX) by administering it together with the plant antioxidants resveratrol and quercetin. Although in use for more than 40... Read more

Lab Technologies

view channel
Image: The Leica DM2500 LED Microscope for clinical laboratories and research applications (Photo courtesy of Leica Microsystems).

New LED Microscope Completes Line of Clinical and Research Tools

A popular microscope used for both clinical and research applications is now available with LED illumination. The Leica (Wetzlar, Germany) DM2500 and DM2500 LED microscopes represent a class of tools... Read more

Business

view channel

Teva Buys Allergan Generic Business Unit

Teva Pharmaceutical Industries (Petah Tikva, Israel) has bought the Allergan (Irvine, CA, USA) generic drugs business for USD 40.5 billion in cash and stock, solidifying its position as the world's largest generic drug maker. Under the terms of the agreement, Teva will pay USD 33.75 billion in cash and USD 6.... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.